Login to Your Account

Mylotarg gets second chance, wins FDA approval in AML

By Staff Reports

Friday, September 1, 2017

Ten years after Pfizer Inc. voluntarily yanked it from the market due to toxicity issues, AML drug Mylotarg is returning to the market, following FDA approval Friday for use in adults with newly diagnosed disease whose tumors express the CD33 antigen.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription